Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Scopolamine is a tropane alkaloid and anticholinergic (antimuscarinic) agent derived from plants of the nightshade family. It acts primarily as a competitive antagonist at muscarinic acetylcholine receptors, inhibiting parasympathetic nerve impulses. Scopolamine is used mainly to prevent nausea and vomiting associated with motion sickness and postoperative recovery from anesthesia or opioid analgesia. It can also be used for gastrointestinal spasms, irritable bowel syndrome, preoperative reduction of respiratory secretions, and other indications such as clozapine-induced drooling or bowel colic. The most common formulation is a transdermal patch applied behind the ear that delivers medication over three days[1][3][4][5][10]. Side effects include dry mouth, blurred vision, drowsiness, confusion, tachycardia or bradycardia, urinary retention, constipation, hallucinations (especially at high doses), and withdrawal symptoms if discontinued after prolonged use[1][4][5]. Scopolamine is listed by the World Health Organization as an essential medicine due to its effectiveness and low cost[9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scopolamine.